Canadian Real-World Experience of Using Sacubitril/Valsartan in Patients With Heart Failure With Reduced Ejection Fraction: Insight From the PARASAIL Study

BACKGROUND: To determine the effectiveness of sacubitril/valsartan 97/103 mg twice daily (b.i.d.) on tolerability, safety, and quality of life (QoL) in Canadian patients with heart failure with reduced ejection fraction in a real-life setting. METHODS: In Prospective, Multicenter, Open Label, Post-A...

Descripción completa

Detalles Bibliográficos
Autores principales: Haddad, Haissam, Bergeron, Sebastien, Ignaszewski, Andrew, Searles, Gregory, Rochdi, Driss, Dhage, Priyanka, Bastien, Natacha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7499388/
https://www.ncbi.nlm.nih.gov/pubmed/32995719
http://dx.doi.org/10.1016/j.cjco.2020.04.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7499388/
https://www.ncbi.nlm.nih.gov/pubmed/32995719
http://dx.doi.org/10.1016/j.cjco.2020.04.007

Ejemplares similares